James Boyer,
James Boyer is a medical doctor specializing in the treatment of autoimmune liver diseases, particularly primary biliary cholangitis (PBC). He has contributed significantly to the understanding and management of PBC through his research and publications. His work focuses on exploring new therapeutic approaches, including next-generation PPAR agonists and IBAT inhibitors. Dr. Boyer is an active member of professional organizations in gastroenterology and hepatology, presenting at conferences and contributing to medical journals.
100%
The Daily's Verdict
This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.
Bias
100%
Examples:
- The author consistently presents information without any indication of personal or subjective opinions.
Conflicts of Interest
100%
Examples:
- No conflicts of interest have been identified.
Contradictions
95%
Examples:
- The author provides consistent information about the therapeutic approaches to PBC and emerging therapies. There are minor discrepancies in some statistics related to the number of people affected by PBC.
Deceptions
100%
Examples:
- The author does not use any deceptive practices in their writing.
Recent Articles
New Drug Iqirvo Approved for Primary Biliary Cholangitis: A Look at Emerging Therapies and Unmet Needs
Broke On: Friday, 21 June 2024The FDA approved Iqirvo (elafibranor) for Primary Biliary Cholangitis (PBC) treatment, showing improvements in biochemical response compared to UDCA alone. Emerging therapies like next-generation PPAR agonists and Ileal bile acid transporter inhibitors (IBAT inhibitors) are promising, reducing cholestasis and improving cognitive impairment and fatigue. Experts emphasize the need for continued observation and validation through further studies. New Drug Iqirvo Approved for Primary Biliary Cholangitis: A Look at Emerging Therapies and Unmet Needs
Broke On: Friday, 21 June 2024The FDA approved Iqirvo (elafibranor) for Primary Biliary Cholangitis (PBC) treatment, showing improvements in biochemical response compared to UDCA alone. Emerging therapies like next-generation PPAR agonists and Ileal bile acid transporter inhibitors (IBAT inhibitors) are promising, reducing cholestasis and improving cognitive impairment and fatigue. Experts emphasize the need for continued observation and validation through further studies. New Drug Iqirvo Approved for Primary Biliary Cholangitis: A Look at Emerging Therapies and Unmet Needs
Broke On: Friday, 21 June 2024The FDA approved Iqirvo (elafibranor) for Primary Biliary Cholangitis (PBC) treatment, showing improvements in biochemical response compared to UDCA alone. Emerging therapies like next-generation PPAR agonists and Ileal bile acid transporter inhibitors (IBAT inhibitors) are promising, reducing cholestasis and improving cognitive impairment and fatigue. Experts emphasize the need for continued observation and validation through further studies. New Drug Iqirvo Approved for Primary Biliary Cholangitis: A Look at Emerging Therapies and Unmet Needs
Broke On: Friday, 21 June 2024The FDA approved Iqirvo (elafibranor) for Primary Biliary Cholangitis (PBC) treatment, showing improvements in biochemical response compared to UDCA alone. Emerging therapies like next-generation PPAR agonists and Ileal bile acid transporter inhibitors (IBAT inhibitors) are promising, reducing cholestasis and improving cognitive impairment and fatigue. Experts emphasize the need for continued observation and validation through further studies.